================================================================================
                    QUALITY AGREEMENT
                    API SUPPLIER QUALIFICATION
================================================================================

                    QUALITY AGREEMENT

Between

BIOPHARMA INDUSTRIES LIMITED ("Buyer")
and
[API SUPPLIER NAME] ("Supplier")

================================================================================

This Quality Agreement ("Agreement") is made and entered into on this [DATE]
day of [MONTH], [YEAR]

BETWEEN

BIOPHARMA INDUSTRIES LIMITED, a company incorporated under the Companies Act,
having its registered office at Plot No. 234-235, MIDC Industrial Area,
Thane-Belapur Road, Rabale, Thane - 400701, Maharashtra, India (hereinafter
referred to as the "Buyer" or "BioPharma")

AND

[SUPPLIER NAME], a company incorporated under [JURISDICTION], having its
registered office at [ADDRESS] (hereinafter referred to as the "Supplier")

RECITALS
--------

A. The Buyer is engaged in the manufacture of pharmaceutical formulations and
   is licensed under the Drugs and Cosmetics Act, 1940.

B. The Supplier is engaged in the manufacture of Active Pharmaceutical
   Ingredients (APIs) and excipients.

C. The Buyer wishes to purchase API/excipients from the Supplier for use in
   its pharmaceutical manufacturing operations.

D. The parties wish to establish quality responsibilities and communication
   channels to ensure the quality of supplied materials meets regulatory and
   pharmacopeial standards.

NOW THEREFORE, in consideration of the mutual covenants contained herein,
the parties agree as follows:

================================================================================

ARTICLE 1: PURPOSE AND SCOPE
---------------------------

1.1 PURPOSE

    The purpose of this Agreement is to define the quality responsibilities
    of each party to ensure that materials supplied by the Supplier meet the
    quality requirements of the Buyer and comply with applicable regulatory
    standards including:

    - Indian Pharmacopoeia (IP)
    - United States Pharmacopeia (USP)
    - British Pharmacopoeia (BP)
    - European Pharmacopoeia (Ph. Eur.)
    - ICH Guidelines
    - Schedule M of Drugs and Cosmetics Rules (India)
    - WHO-GMP requirements

1.2 SCOPE

    This Agreement covers the following material(s) supplied by the Supplier:

    Material Name:          [API/EXCIPIENT NAME]
    CAS Number:             [CAS NUMBER]
    Grade:                  [Pharmacopeial grade - IP/USP/BP/Ph.Eur.]
    Intended Use:           Active Pharmaceutical Ingredient for oral solid
                            dosage forms
    DMF Reference:          [DMF Number, if applicable]

1.3 RELATIONSHIP TO COMMERCIAL AGREEMENT

    This Quality Agreement supplements but does not supersede the commercial
    supply agreement between the parties. In case of conflict, the terms
    more favorable to product quality shall prevail.

================================================================================

ARTICLE 2: REGULATORY REQUIREMENTS
---------------------------------

2.1 SUPPLIER CERTIFICATIONS

    The Supplier represents and warrants that it holds the following
    certifications:

    (a) Drug Manufacturing License: [License Number]
    (b) WHO-GMP Certificate: [Certificate Number]
    (c) US FDA Registration (if applicable): FEI [Number]
    (d) CEP (Certificate of Suitability) - for EU markets
    (e) ISO Certification: [If applicable]

2.2 DRUG MASTER FILE (DMF)

    The Supplier has filed a Drug Master File with:
    - CDSCO India: DMF Number [Number]
    - US FDA: DMF Number [Number]
    - [Other authorities as applicable]

    The Supplier authorizes the Buyer to reference the DMF for regulatory
    filings.

2.3 REGULATORY INSPECTIONS

    The Supplier shall:
    (a) Notify the Buyer of any regulatory inspection within 48 hours
    (b) Provide copies of inspection reports and observations
    (c) Inform the Buyer of any adverse regulatory action
    (d) Permit the Buyer to accompany during inspections if requested by
        regulatory authorities

================================================================================

ARTICLE 3: SPECIFICATIONS AND TESTING
------------------------------------

3.1 SPECIFICATIONS

    The material shall comply with the specifications set out in Annexure A.

    The specifications include:
    - Identity tests
    - Assay limits
    - Related substances / impurity profile
    - Residual solvents
    - Heavy metals
    - Microbial limits
    - Physical characteristics (particle size, bulk density, etc.)

3.2 CERTIFICATE OF ANALYSIS (CoA)

    The Supplier shall provide a Certificate of Analysis with each batch:

    CoA Requirements:
    (a) Batch number and manufacturing date
    (b) Expiry/Retest date
    (c) Test results for all specification parameters
    (d) Pharmacopeial reference (IP/USP/BP)
    (e) Analyst signature and date
    (f) QA approval signature

3.3 TESTING RESPONSIBILITIES

    Testing Party                 Supplier    Buyer
    -----------------------------------------------
    Identity                      Yes         Yes
    Assay                         Yes         Yes
    Related Substances            Yes         Yes
    Residual Solvents             Yes         No*
    Heavy Metals                  Yes         No*
    Microbial Limits              Yes         Yes
    Physical Tests                Yes         Yes

    * Buyer may test periodically or when concerns arise

3.4 REFERENCE STANDARDS

    The Supplier shall use pharmacopeial reference standards or qualified
    working standards traceable to pharmacopeial standards.

3.5 TEST METHODS

    The Supplier shall use validated analytical methods as per ICH Q2(R1).
    Method validation reports shall be available for audit.

================================================================================

ARTICLE 4: MANUFACTURING AND PROCESS CONTROLS
--------------------------------------------

4.1 MANUFACTURING SITE

    The material shall be manufactured at:
    [Site Name and Address]

    Manufacturing shall not be transferred to another site without prior
    written approval from the Buyer.

4.2 GMP COMPLIANCE

    The Supplier shall manufacture the material in compliance with:
    (a) Current Good Manufacturing Practices (cGMP)
    (b) ICH Q7 - GMP for APIs
    (c) Applicable pharmacopeial requirements
    (d) Supplier's registered manufacturing process

4.3 PROCESS VALIDATION

    The Supplier shall:
    (a) Validate all critical manufacturing processes
    (b) Maintain validation status through ongoing verification
    (c) Revalidate upon significant process changes
    (d) Provide validation summaries upon request

4.4 CLEANING VALIDATION

    The Supplier shall:
    (a) Validate cleaning procedures for equipment
    (b) Establish and justify residue limits
    (c) Prevent cross-contamination

4.5 CHANGE CONTROL

    The Supplier shall not make any of the following changes without prior
    written approval from the Buyer (minimum 60 days advance notice):

    (a) Change in manufacturing site
    (b) Change in synthesis route or process
    (c) Change in critical raw material source
    (d) Change in specifications
    (e) Change in packaging
    (f) Change in testing methods (if affecting results)
    (g) Change in equipment affecting product quality

    Change notification shall include impact assessment and supporting data.

================================================================================

ARTICLE 5: DOCUMENTATION AND RECORDS
-----------------------------------

5.1 BATCH RECORDS

    The Supplier shall:
    (a) Maintain complete batch manufacturing records
    (b) Retain records for minimum 1 year after expiry or 5 years from
        manufacture, whichever is longer
    (c) Provide copies upon request (within 5 business days)

5.2 TRACEABILITY

    The Supplier shall maintain traceability of:
    (a) All raw materials used
    (b) Manufacturing equipment
    (c) Personnel involved
    (d) Environmental conditions
    (e) Distribution to customers

5.3 STABILITY DATA

    The Supplier shall:
    (a) Conduct stability studies per ICH guidelines
    (b) Establish and justify shelf life / retest period
    (c) Provide stability data upon request
    (d) Notify of any stability failure

================================================================================

ARTICLE 6: PACKAGING AND LABELING
--------------------------------

6.1 PACKAGING REQUIREMENTS

    The material shall be packaged in:
    - Container: [HDPE drums / Fiber drums with PE liner]
    - Closure: [Tamper-evident seal]
    - Pack size: [25 kg / 50 kg]

    Packaging shall protect the material from moisture, light, and
    contamination during storage and transportation.

6.2 LABELING REQUIREMENTS

    Each container shall be labeled with:
    (a) Material name and grade
    (b) Batch number
    (c) Manufacturing date
    (d) Expiry/Retest date
    (e) Net weight
    (f) Storage conditions
    (g) Manufacturer name and address
    (h) "For pharmaceutical use" or equivalent
    (i) Safety/handling precautions

6.3 SHIPPING DOCUMENTATION

    Each shipment shall include:
    (a) Certificate of Analysis
    (b) Packing list
    (c) Safety Data Sheet (SDS)
    (d) Country of origin certificate (if required)

================================================================================

ARTICLE 7: SUPPLIER QUALIFICATION AND AUDITS
-------------------------------------------

7.1 INITIAL QUALIFICATION

    Prior to first supply, the Supplier has been qualified through:
    (a) Questionnaire review
    (b) Document review (licenses, certificates, DMF)
    (c) On-site GMP audit
    (d) Sample testing and qualification

    Initial Audit Date: [DATE]
    Audit Outcome: [Approved / Approved with conditions]

7.2 PERIODIC AUDITS

    The Buyer reserves the right to conduct periodic audits:
    (a) Regular audits: Every 2-3 years
    (b) For-cause audits: At any time if quality concerns arise

    The Supplier shall provide reasonable access to facilities, records, and
    personnel during audits.

7.3 AUDIT FINDINGS AND CAPA

    The Supplier shall:
    (a) Respond to audit findings within 30 days
    (b) Implement corrective and preventive actions
    (c) Provide evidence of CAPA effectiveness

================================================================================

ARTICLE 8: QUALITY ISSUES AND COMPLAINTS
---------------------------------------

8.1 NON-CONFORMING MATERIAL

    If the Buyer finds material non-conforming to specifications:
    (a) Buyer shall notify Supplier within 15 days of receipt
    (b) Supplier shall investigate and respond within 15 days
    (c) Supplier shall replace non-conforming material at no cost
    (d) Supplier shall conduct root cause analysis and implement CAPA

8.2 CUSTOMER COMPLAINTS

    If the Buyer receives complaints related to Supplier's material:
    (a) Buyer shall notify Supplier within 5 business days
    (b) Supplier shall investigate and respond within 15 days
    (c) Supplier shall provide investigation report
    (d) Both parties shall collaborate on CAPA if required

8.3 FIELD ALERTS AND RECALLS

    If a quality issue requires field action:
    (a) Supplier shall notify Buyer immediately
    (b) Both parties shall cooperate in investigation
    (c) Supplier shall support any recall with documentation and resources
    (d) Supplier shall bear costs if recall is due to Supplier's fault

================================================================================

ARTICLE 9: CONFIDENTIALITY
-------------------------

9.1 CONFIDENTIAL INFORMATION

    Each party shall keep confidential all information received from the
    other party including:
    (a) Technical information and know-how
    (b) Manufacturing processes
    (c) Specifications and test methods
    (d) Business information
    (e) Regulatory filings

9.2 EXCEPTIONS

    Confidentiality obligations do not apply to information:
    (a) Already in public domain
    (b) Required to be disclosed to regulatory authorities
    (c) Required by law

9.3 SURVIVAL

    Confidentiality obligations survive termination for 5 years.

================================================================================

ARTICLE 10: COMMUNICATION AND CONTACTS
-------------------------------------

10.1 QUALITY CONTACTS

     For BioPharma (Buyer):
     Name:       Mrs. Deepika Sunil Jain
     Title:      Head of Quality Assurance
     Email:      qa.head@biopharma.com
     Phone:      +91-22-2568-XXXX

     For [Supplier]:
     Name:       [Name]
     Title:      [Title]
     Email:      [Email]
     Phone:      [Phone]

10.2 EMERGENCY CONTACTS

     For urgent quality matters (recalls, safety issues):
     BioPharma: +91-98XXX-XXXXX (24/7)
     Supplier:  [24/7 Emergency Number]

10.3 REGULAR COMMUNICATION

     The parties shall hold quality review meetings:
     - Frequency: Quarterly (or as needed)
     - Topics: Quality metrics, complaints, changes, audits

================================================================================

ARTICLE 11: TERM AND TERMINATION
-------------------------------

11.1 TERM

     This Agreement shall be effective from [DATE] and shall continue for
     a period of 3 (three) years unless terminated earlier.

11.2 RENEWAL

     This Agreement shall automatically renew for successive 1-year periods
     unless either party provides 90 days' written notice of non-renewal.

11.3 TERMINATION FOR CAUSE

     Either party may terminate this Agreement immediately if:
     (a) The other party materially breaches this Agreement and fails to
         cure within 30 days of notice
     (b) The other party's manufacturing license is suspended or cancelled
     (c) The other party becomes insolvent or bankrupt

11.4 CONSEQUENCES OF TERMINATION

     Upon termination:
     (a) Supplier shall complete pending orders unless otherwise agreed
     (b) Confidentiality and records retention obligations survive
     (c) Pending quality investigations shall be completed

================================================================================

ARTICLE 12: GENERAL PROVISIONS
-----------------------------

12.1 GOVERNING LAW

     This Agreement shall be governed by the laws of India.

12.2 DISPUTE RESOLUTION

     Disputes shall be resolved through good faith negotiations. If unresolved,
     disputes shall be subject to arbitration in Mumbai under the Arbitration
     and Conciliation Act, 1996.

12.3 AMENDMENT

     This Agreement may only be amended by written instrument signed by both
     parties.

12.4 ENTIRE AGREEMENT

     This Agreement, together with its Annexures, constitutes the entire
     agreement between the parties regarding quality matters.

================================================================================

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.

FOR BIOPHARMA INDUSTRIES LIMITED:

Signature: _______________________
Name: Mrs. Deepika Sunil Jain
Title: Head of Quality Assurance
Date: [DATE]

Signature: _______________________
Name: Dr. Ramesh Narayan Kulkarni
Title: Managing Director
Date: [DATE]

FOR [SUPPLIER NAME]:

Signature: _______________________
Name: [Name]
Title: [Title]
Date: [DATE]

Signature: _______________________
Name: [Name]
Title: [Title]
Date: [DATE]

================================================================================

ANNEXURE A: SPECIFICATIONS
-------------------------

Material: [API NAME]
Grade: [IP/USP/BP/Ph.Eur.]

Parameter                    Specification              Test Method
------------------------------------------------------------------------
Description                  [White crystalline powder] Visual
Identification A (IR)        Matches reference          IP/USP
Identification B (HPLC)      RT matches reference       In-house
Assay                        98.0 - 102.0%              HPLC (IP/USP)
Related Substances
  - Any individual impurity  NMT 0.2%                   HPLC
  - Total impurities         NMT 1.0%                   HPLC
Residual Solvents            Per ICH Q3C                GC
Heavy Metals                 NMT 20 ppm                 ICP-OES
Sulphated Ash                NMT 0.1%                   IP/USP
Loss on Drying               NMT 0.5%                   IP/USP
Microbial Limits
  - TAMC                     NMT 1000 CFU/g             IP/USP
  - TYMC                     NMT 100 CFU/g              IP/USP
  - E. coli                  Absent/g                   IP/USP
  - Salmonella               Absent/10g                 IP/USP
Particle Size (D90)          NMT 100 microns            Laser diffraction

================================================================================

ANNEXURE B: LIST OF CRITICAL RAW MATERIALS
-----------------------------------------

[List of starting materials and key intermediates for the API]

================================================================================

ANNEXURE C: APPROVED SUBCONTRACTORS
----------------------------------

[List of approved contract testing labs, packaging vendors, etc.]

================================================================================
                    END OF QUALITY AGREEMENT
================================================================================
